NCT06850337Not yet recruiting
Megakaryocyte Heterogeneity in Sickle Cell Disease
Characterization of Megakaryocytic Subpopulations and the "Immune" Phenotype of Platelets of the Sickle Cell Disease Patient
Source: ClinicalTrials.gov · Last updated 25 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crisis called vaso-occlusive crisis (VOC) and chronic inflammation. Activated platelets of SCD patients participated to both chronic inflammation and painful VOC. Platelets are anucleated cells from the fragmentation of megakaryocytes in bone marrow. The main aim of this study is to characterize the distribution of the different megakaryocyte subpopulations of sickle cell disease patients SS and SC and in particular the "immune" megakaryocytes CD148+CD48+ and to compare it with the platelet phenotype.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 24 Feb 2025
- Start date
- Jul 2025
- Primary completion date
- Mar 2027
- Lead sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
- Diseases
- Sickle cell disease
- NCT number
- NCT06850337
What you commit to
- Study type: Observational
- Planned participants: 100
- From Jul 2025 to the primary completion date, Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- patients with a transfusion therapy or on bleeding therapy for less than three months
Age
- patients younger than 18 years old
Other
- patients with hemoglobinopathy other than SS and SC SCD
- patients no affiliated to national social security
- pregnant or breastfeeding patients
Who the study is looking for
- patients with SS or SC SCD
- diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies
- patients older than 18 years at inclusion
- clinically in a steady state at inclusion (without complication in the last month and without transfusion in the three last months)
- patient followed up for SCD at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe à Pitre)
- patients who will provide written informed consent in accordance with the Declaration of Helsinki
- patients affiliated to national social security
- the control group (AA subjects) will be patients older than 18 years old who come at the University hospital of Guadeloupe, (Pointe à Pitre) for hip or knee replacement and will do not suffer from chronic disease.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de la Guadeloupe Coordinator of this site? Confirm its status | Pointe-à-Pitre | Guadeloupe | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.